Head to Head Comparison: Cogentix Medical (CGNT) vs. Mazor Robotics (MZOR)

Cogentix Medical (NASDAQ: CGNT) and Mazor Robotics (NASDAQ:MZOR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cogentix Medical and Mazor Robotics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogentix Medical 0 0 3 0 3.00
Mazor Robotics 2 5 1 0 1.88

Cogentix Medical presently has a consensus target price of $4.58, indicating a potential upside of 59.14%. Mazor Robotics has a consensus target price of $40.00, indicating a potential downside of 33.93%. Given Cogentix Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Cogentix Medical is more favorable than Mazor Robotics.

Profitability

This table compares Cogentix Medical and Mazor Robotics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cogentix Medical -36.14% -11.52% -10.04%
Mazor Robotics -19.08% -14.03% -11.65%

Insider & Institutional Ownership

13.3% of Cogentix Medical shares are held by institutional investors. Comparatively, 26.4% of Mazor Robotics shares are held by institutional investors. 62.7% of Cogentix Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cogentix Medical and Mazor Robotics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cogentix Medical $51.85 million 3.38 -$22.09 million ($0.41) -7.02
Mazor Robotics $64.95 million 23.79 -$18.66 million ($0.51) -118.71

Mazor Robotics has higher revenue and earnings than Cogentix Medical. Mazor Robotics is trading at a lower price-to-earnings ratio than Cogentix Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cogentix Medical has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Mazor Robotics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.

Summary

Cogentix Medical beats Mazor Robotics on 8 of the 14 factors compared between the two stocks.

Cogentix Medical Company Profile

Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.

Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply